SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

Germany's foreign intelligence service, the BND, reportedly concluded in 2020 that there was an 80% to 90% probability that ...

SARS-CoV-2 between 2021 and 2023 developed long-COVID, and in more than half of them the symptoms persisted for two years.

Bispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...

New findings add weight to the theory that COVID-19 originated at the Wuhan Institute of Virology. Experts point to lax ...

SARS-CoV-2 has been evolving the ability to evade the immune system about twice as fast as the fastest-evolving flu virus. It averages more than a dozen significant changes every year.

Five years after the World Health Organization declared a global pandemic, there has been progress — and backsliding in the ...

But what if you could avoid getting COVID-19 altogether? That’s the potential promise of a new study on a drug made by ...

Research identifies how viral respiratory infection damages macrophages and suggests treatment with a pre-existing FDA approved drug.

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

Results saw all 24 healthy volunteers who made it to the 72-week mark still had effective levels of dMAB in their systems.